News

Expanding rapid testing stands out as an affordable way to help mitigate risks associated with COVID-19 and emerging variants. Infectious disease researchers at The University of Texas at Austin have developed a new model that tailors testing recommendations to new variants and likely immunity levels in a community, offering a new strategy as public health leaders seek a way out of a pandemic that has so far thwarted the best efforts to end its spread. It is the first study to identify optimal levels of testing in a partially immunized population.

Until COVID-19, few people alive today had experienced the chaos and destruction of a really bad pandemic, one that has at times ground businesses, schools and social lives to a near standstill and killed millions globally. But did you know that we aren't alone in being battered by a global infectious disease? Frogs are also struggling through their own pandemic that, according to biologist Kelly Zamudio, has several eerie parallels with COVID-19. Perhaps our own encounters with a pandemic will give us new sympathy for our slimy, bug-eyed friends.

UT Austin structural biologist Jason McLellan, Ph.D., is the recipient of the 2022 Edith and Peter O'Donnell Award in Medicine from TAMEST (The Academy of Medicine, Engineering and Science of Texas). He was chosen for his breakthrough research in mapping, modifying, and stabilizing coronavirus spike proteins, which paved the way for the creation of leading COVID-19 vaccines.

Few developments have rocked the biotechnology world or generated as much buzz as the discovery of CRISPR-Cas systems, a breakthrough in gene editing recognized in 2020 with a Nobel Prize. But these systems that naturally occur in bacteria are limited because they can make only small tweaks to genes. In recent years, scientists discovered a different system in bacteria that might lead to even more powerful methods for gene editing, given its unique ability to insert genes or whole sections of DNA in a genome.

Early last year, Jimmy Gollihar was deep into building a unique facility on the Forty Acres, what he calls "the biological foundry" – a turbo-charged, biotech playground with a focus on rapid scientific discovery. The foundry was to be a key element of a partnership in synthetic biology research between The University of Texas at Austin and the U.S. military. Then, as fate would have it, COVID-19 would change everything.

Using the same approach they recently used to create effective vaccine candidates against COVID-19 and respiratory syncytial virus (RSV), scientists are tackling another virus: the tick-borne Crimean-Congo hemorrhagic fever (CCHF). It causes death in up to 40% of cases, and the World Health Organization identified the disease as one of its top priorities for research and development. The results appear today in the journal Science.

Jason McLellan, UT Austin molecular biosciences professor, has received the 2021 Shirley Bird Perry Longhorn Citizenship Award, recognizing the wide-reaching impact of his work with viral proteins, especially his contributions to COVID-19 vaccines. The award is given annually by UT Austin's Annette Strauss Institute for Civic Life.

Imagine biological and chemical imaging tools so advanced that they are able to show the molecular details of a virus as it attaches to and enters cells, or the alignment of vanishingly tiny crystals at an atomic level so as to lend insights for new solar energy technology.

Antibiotic resistance, where disease-causing bacteria evolve resistance to drugs that usually kill them, is a rising problem globally, meaning new antibiotics need to be found. However, it is difficult for researchers to know which parts of bacterial cells to target with new drugs.